ABSTRACT
overgrowth, uncontrolled thyroid disease or diabetes). Patients with previous GI or intestinal (large or small bowel) surgery, with the exception of appendectomy or cholecystectomy, were also excluded. Patients reporting symptoms suggestive of organic diseases were excluded from the study and also women who were pregnant or breastfeeding or patients who had undergone previous diagnostic testing for their IBS symptoms were excluded from the study.
No participants had been previously tested for thyroid function. Ethical clearance was taken as per the guidelines of the research Unit of Institute of Medicine.
Collection of Blood Samples
Venous blood sample (2-3 ml) was collected from antecubital vein in a plain vial, and was allowed to clot, and then subsequently serum was separated by centrifugation at 3000 g for 10 minutes and stored at -20 °C until thyroid hormones were estimated.
Assay procedure of thyroid hormones
The thyroid hormones (fT3, fT4 and TSH) were assayed by Vitros ECIQ analyser. The reference range used for fT3 was 4.2-8.1 pmol/L, for fT4 were 10-28.2 pmol/ L and for TSH was 0.4-4.6 mIU/mL.Thyroid function was considered normal (Euthyroidism) when subjects had all the three hormones within the reference range. Abnormal thyroid function was further categorized as hyperthyroidism (increased fT3, fT4 and low TSH), subclinical hyperthyroid (both fT3 and fT4 are normal but low TSH), hypothyroidism (low fT3, fT4 and high TSH) and subclinical hypothyroidism (fT3, fT4 are normal but high TSH level) (Peter, 2009; Helfand and Redfern, 1998) .
Principle of the Assay
The quantitative immunoenzymatic determination of TFT (TSH, T3 & T4) is based on the ELISA (Enzyme-linked Immunosorbent Assay) technique. The assay system utilizes two monoclonal antibodies specific for different antigenic determinants of each of the (TSH, T3 & T4). The first antibody is immobilized on the surface of the microtiter wells. The second antibody is conjugated to horseradish peroxidase. The test sample is allowed to react simultaneously with the two antibodies, resulting in the (TSH, T3 & T4) molecules being sandwiched between the solid phase and the enzyme linked antibodies. After an incubation step, the wells are washed with Washing Solution to remove all unbound material. The immune complex is visualized by adding Tetramethylbenzidine (TMB) substrate which gives a blue reaction product. The intensity of this product is proportional to the concentration of (TSH, T3 & T4) in the specimen. Sulphuric acid is added to stop the reaction. This produces a yellow stool (IBS-U). The condition is characterized by a scarcity of biological markers; thus, diagnostic definitions and classifications have relied to a large extent on symptoms, typically distinguished by persistent or recurrent abdominal pain related to defecation and/or chronic disturbance of bowel [3] [4] [5] habits. The true incidence of gastrointestinal manifestations of patients with functional abnormalities of the thyroid is not well documented. Gastrointestinal motor dysfunction, manifested by altered intestinal motility and transit time, has widely been accepted as the leading cause of gastrointestinal 6 symptoms of thyroid disease. Patients with hyperthyroidism can experience frequent bowel movements, diarrhea, even [6] [7] [8] malabsorption with steatorrhea.
Chronic dyspeptic symptoms such as epigastric pain and fullness, as well as eructation, nausea and vomiting are also frequently seen in these patients. Less commonly, hyperthyroidism has been 9 reported to cause persistent and intractable vomiting. The overall decreased metabolic function seen in patients with hypothyroidism manifests in the GI tract with sluggish intestinal motility, ranging from mild constipation to paralytic 10 ileus and colonic pseudoobstruction. While thyroid disorder should be considered in the differential diagnosis of patients with IBS symptoms, it is not clear if thyroid dysfunction amongst patients with IBS is high enough to warrant routine screening. Herein the findings from the prospective, crosssectional study has been analysed to see thyroid dysfunction in patients with IBS.
MATERIALS AND METHODS
This was a cross-sectional study conducted in the Gastroenterology OPD of the Tribhuvan University Teaching Hospital, Kathmandu, Nepal from May 2015 to February 2016. There was one study population who were consecutive adult patients with symptoms suggestive of IBS presented in the Gastroenterology OPD. Patients with suspected IBS fulfilled the Rome III criteria for IBS based on their responses 11 to a questionnaire administered in the OPD. Patients were excluded from the study if they had been previously diagnosed with comorbid conditions that could have explained their GI symptoms (e.g. celiac disease, colon cancer, inflammatory bowel disease (IBD), scleroderma, small intestinal bacterial endpoint colour. Absorbance is read using an ELISA microwell plate reader. The color intensity is directly proportional to the concentration of (TSH, T3 & T4) present in the test sample (instruction manual for autobio diagnostics Thyroid ELISA kits).
Statistical Analysis
Statistical analysis was done using Excel system version 2007 and includes descriptive statistics (mean and standard deviation) and inferential statistics (Chi-square test) to test the significance of difference. When P value is less than 0.05, the difference is considered significant, and the difference is considered highly significant when P-value was less than 0.001.
RESULTS
A total of 80 patients with symptoms suggestive of IBS were enrolled in the study from May 2015 to February 2016. There were 42 (52.5%) females and 38 (47.5%) males with age range of 62 with minimum of 18 and maximum of 80 years. The mean age was 34 years. Majority of the subjects were female.
Among them 47 were Irritable Bowel Syndrome Diarrhea predominant (IBS-D), 18 were Irritable Bowel Syndrome Constipation predominant (IBS-C), 8 were Irritable Bowel Syndrome unsubtype (IBS-U) and 7 were Irritable Bowel Syndrome Mixed (IBS-M).
In this study, subjects are divided according to the thyroid status which shows subclinical hypothyroidism 12 (15%), overt hypothyroidism 2 (2.5%), overt hyperthyroidism 1 (1.25%) and euthyroidism 65 (81%) as shown in Fig 1 pie chart.
Overall prevalence of thyroid disorder was found to be 19% with subclinical hypothyroidism being the most common 15.0%. Table 1 shows the overall statistics of thyroid hormones. Fig 2 shows the prevalence of thyroid dysfunction among different subgroups of IBS. The prevalence of thyroid dysfunction was 19% in IBS-D, 27.8% in IBS-C, 14% in IBS-M and no dysfunction in IBS-U. There was no significant difference in prevalence of thyroid dysfunction among different subgroups of IBS (Pearson Chi-square = 2.906, Pvalue = .406). Fig 3 shows the prevalence of different types of thyroid dysfunction among different IBS subtypes. Out of 47 IBS-D patients, subclinical hypothyroidism was present in 8 and overt hypothyroidism in 1 whereas 38 were euthyroid. Out of 18 IBS-C patients, subclinical and overt hypothyroidisms were present in 4 and 1 respectively whereas 13 were euthyroid. There was 1 overt hyperthyroidism out of 7 patients with IBS-M whereas 6 were euthyroid. All 8 patients of IBS-U were euthyroid. 
DISCUSSION
In the present study more than half of the subjects are females indicating that more females are suffering from thyroid 12, 13 illness. This finding is supported by few studies. The National Health and Nutrition Examination Survey (NHANES 1999-2002) of 4392 individuals reflecting the US population reported hypothyroidism in 3.7% of the general 14 population. In a population-based study done in Cochin, India on 971 adult subjects, the prevalence of hypothyroidism 15 was 3.9% and subclinical hypothyroidism was 9.4%.
The prevalence of thyroid disorders seen in a study conducted in high risk groups at tertiary center in IOM, TUTH, Nepal 16 was 29.0%. Similar study observed 30% of the population suffering from thyroid dysfunction in high risk groups at a 17 tertiary referral center in eastern Nepal. The worldwide prevalence of hypothyroidism in various studies shows a remarkable variation and current prevalence ranges from 1% 18 to 20% for sub-clinical and 1-2% for overt hypothyroidism.
In our study, the prevalence of thyroid dysfunction in IBS i.e. 19% was higher than in general population that were 14 15 conducted in USA and India. However it was comparable to 16, 17 the study conducted in high risk groups. In the present study since the prevalence of thyroid dysfunction in IBS was high which clearly indicates that IBS is a high risk group for the possible association of thyroid dysfunction.
According to the results of the current study, altered thyroid function was found in patients with suspected IBS. These findings were in disagreement with the findings of Hamm et. 19 at who failed to modify the criteria for diagnosis of IBS. The mechanism behind our results was not clear; however, direct hormonal effects or stimulatory actions in the central nervous system have been suggested. Treatment of the thyrotoxicosis with beta blocking agents and anti-thyroid drugs greatly 20 improves these symptoms. The exact biochemical mechanisms by which thyroid disorders affect the gastrointestinal system are not fully understood. Changes may be seen on a molecular level with alteration of hormone receptors, dysfunction of the autonomic nervous system and myoelectrical enteric activity, as well as changes on a tissue 21 level in the form of myopathy. Hormonal effects on the GI tract may be a direct result of thyroid hormone, or as a result of synergistic effects of catecholamines. Tenore et al. investigated the effect of thyroxin (T4) on the intestinal chloride/bicarbonate exchange in hypo-and hyperthyroid rats. They found that alterations in intestinal ion exchange, mainly the flux of chloride, led to mucosal effects and resultant diarrhea. These findings were not seen when T4 was added ex vivo to rat ileum, suggesting that the effect on 22 electrolyte transport likely requires systemic factors. Furthermore, the beta-adrenergic antagonist propranolol inhibits intestinal transit in hyperthyroidism, thereby indicating that some of the dysmotility may be mediated 23 through the adrenergic/catecholamine system. Dysfunction of the autonomic nervous system (ANS) may modify the neuro-hormonal milieu, and result in alterations of myoelectric activity. However, there are no clear data regarding the exact mechanisms involved. Hypothyroidism characteristically results in accumulation of glycosaminoglycans, mostly hyaluronic acid, in interstitial tissues throughout the body. This leads to interstitial edema that is particularly evident in the skin, heart muscle, and skeletal muscle, but also in the gastric smooth muscle. Edema in the gastric muscle may predispose to abnormalities of gastric myoelectric activity and 24 thus the dysmotility seen in hypothyroid patients. Examination of TFTs in patients with an established history of IBS revealed an altered function of thyroid comparable to that in the general population; this might be attributed to high 25 incidence of thyroid problems in older adults.
CONCLUSION
The prevalence of thyroid dysfunction in IBS patients is high. Therefore, the routine thyroid function tests in the diagnostic evaluation of established IBS patients should be recommended.
